Apolipoprotein C3 C1100T and C3238G Polymorphisms and Cardiovascular Disease Risk among Obese Type 2 Diabetics in Southwestern Nigeria
DOI:
https://doi.org/10.4314/ajbr.v27i1.12Parole chiave:
apolipoprotein C3 polymorphism, cardiovascular disease, NigerianAbstract
Obesity is associated with cardiovascular disease (CVD) risk and type 2 diabetes mellitus (T2DM). Apolipoprotein (APO) C3 C3238G and C1100T gene polymorphisms are risk factors for CVD but their relationship with obesity and T2DM in Black Africans has not been fully elucidated. Association of these gene polymorphisms with hypertension and dyslipidemia among obese type 2 diabetics in a Southwest Nigerian population was assessed.One hundred and thirty-eight (138) non-obese diabetics, 107 obese diabetics, 100 obese non-diabetics and 100 control subjects attending metabolic clinic in Osun State Nigeria were enrolled. Anthropometric parameters were measured. Fasting blood sugar (FBS), lipid profile and APOC3 protein were estimated using standard lab procedures. APOC3 gene polymorphisms were analyzed by polymerase chain reaction - restriction fragment length polymorphism. Data were analyzed and significant level set at p<0.05. APOC3238G G allele was associated with higher risk of hypertension (OR=2.39, 95%CI=1.03-5.53; p=0.042) in obese diabetics compared to other groups. Highest frequency for hypertension was observed among obese diabetics expressing CC than CG and GG genotypes. GG genotype was associated with dyslipidemia in obese diabetic subjects exhibiting APO C3 C3238G single nucleotide polymorphism (SNP). Homozygous CC genotype showed highest frequency (χ2: 25.515, p<0.05) than other genotypes and was associated with increased atherogenic indices among obese diabetic subjects expressing APO C3 C1100T SNP. APOC3 C1100T gene and polymorphic alleles of the G variant of APOC3 C3238G gene were associated with dyslipidemia and hypertension in obese T2DM individuals, thereby contributing to increased risk of CVD among the studied population
Riferimenti bibliografici
Abubakari A., Lauder W., Agyemang C., Jones M., Kirk A. (2008): Prevalence and time trends in obesity among adult West African population: a meta analysis. Obesity reviews. 9(4):297-311.
Alla L., Dov G., Marina S. (2014): Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health. Cardiovascular Diabetology. vol 13, Article no 141.
American Diabetes Association. (2014): Diagnosis and classification of diabetes mellitus Diabetes Care. 37(Suppl. 1): S81-S90.
Boren J., Packard C.J., Taskinen M. (2020): The roles of APOCIII on metabolism of triglceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 11:474. Doi:10.3389/fendo.2020.00474.
Bruce D.F. (2018): Prehypertension: Are you at risk? Hypertension/ High blood pressure guide. March 2018. Reviewed by C. Dertsartassian. www.webmd.com
Cui F, Li K, Li Y, Zhang X, An C. (2014): apolipoproteinC3 genetic polymorphisms are associated with lipids and Coronary Artery Disease in Chinese population. Lipids Health Dis. 13:170.
Hamer M., Bostock S., Hackett R. (2013): Objectively assessed sedentary time and type 2 diabetes mellitus: a case-control study. Diabetologia. 56(12):2761-2.
Hiukka A., Stahlman M., Petterson C., Adiels M., Teneberg S. (2009): ApoCIII enriched LDL in Type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomelinase. Diabetes . 2018-2026.
Iloh G.A.N., Amadi A., Nwankwo B.O., Ugwu V.C. (2011): Obesity in adult Nigerians: A study of its pattern and common primary co-morbidities in a rural Mission General Hospital in Imo State, South-eastern Nigeria. Nigeria Journal of Clinical Practice. 14(2):212-218.
Innocent I.C., Abali C., Collins J., Ohagwu K.A., Imoh M.E. (2013): Prevalence of overweight and obesity in adult Nigerian- a systematic review. Diabetes. 43-47.
Jerant A., Bertakis K.D., Franks P. (2015): Body mass index and health status in diabetic and non-diabetic individuals. Nutr Diabetes. 27;5(4):e152. Doi:10.1038/nutd.2015.2.
Jo G., Kwak S., Kim J.Y., Lim H., Shin M. (2018): Association between genetic variant of apolipoproteinC3 and incident hypertension stratified by obesity in Korea. Nutrients 10(11):1595.
Kearns K., Dee A., Perry I. (2014): Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level. BMC Public Health 14, 143. Doi: 10.1186/1471-2458-14-143
Klop B, Elte JWF, Cabezas MC. (2013): Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 5(4), 1218-1240. 10.3390/nu5041218.
Kohan A.B. (2015): Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes.;22(2):119–25.
Li YH, Liu L (2014). Apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins modulate adipocyte triglyceride content. Lipids Health Dis.;13(1):136.
Mercado-Gonzales S.I., Carpio-Rodríguez A.N., Carrillo-Larco R.M., Bernabé-Ortiz A. (2019): Sleep Duration and Risk of Obesity by Sex: Nine-Year Follow-Up of the Young Lives Study in Peru. Child Obes. 15(4):237-243. [PubMed]
Pereira T. Kelishandi R. (2012): Dyslipidemia and cardiovascular risk: lipid ratios as risk factors for cardiovascular disease. Dyslipidemia – From Prevention to Treatment. Rijeka. Croatia: InTech Europe. pp. 279–302.
Raposo H.F., Paiva A.A., Kato L.S. (2015): Apolipoprotein CIII overexpression exacerbates diet-induced obesity due to adipose tissue higher exogenous lipid uptake and retention and lower lipolysis rates. Nutr Metab (Lond) 12, 61 https://doi.org/10.1186/s12986-015-0058-6
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt S.M., Khaw K.T., Gudnason V. (2007): Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 115: 450-458. 10.1161/circulationaha.106.637793
Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P: (1999): ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation. 99: 1872-1877. 10.1161/01.CIR.99.14.1872
World Health Organization. (2012): Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organization; Geneva p. 253.
World Health Organization (2016). Obesity and overweight. Geneva: World Health Organization,.
Wulff A.B., Nordestgaard B.G., Tybjaerg-Hansen A. (2018): APOC3 Loss- of- function mutations, remnant cholesterol, low-density lipoprotein cholesterol and cardiovascular risk: Mediation and Meta-analyses of 137895 individuals. Arterioscler Thromb Vasc Biol. 38:660-668. Doi:10.1161/atvbaha.117.310473.
Xavier P. (2009): The Medical Risks of Obesity. Journal Postgrad Med. 121(6): 21–33.doi: 10.3810/pgm.2009.11.2074
Dowloads
Pubblicato
Fascicolo
Sezione
Licenza
Copyright (c) 2024 African Journal of Biomedical Research
Questo volume è pubblicato con la licenza Creative Commons Attribuzione 4.0 Internazionale.
